13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • MK-1308-001-00

    Acronym: 

    MK-1308-001-00

    ACTRN/NCT /ethics: 

    Scientific title: 

    A Phase 1 open-label, multi-arm, multicentre study of MK-1308 in combination with pembrolizumab forsubjects with advanced solid tumours

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase I Tumour Stream NSCLC/SCLC
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream NSCLC/SCLC
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A Phase 1 open-label, multi-arm, multicentre study of MK-1308 in combination with pembrolizumab for subjects with advanced solid tumours

    Lay Summary

    A Phase 1 open-label, multi-arm, multicentre study of MK-1308 in combination with pembrolizumab forsubjects with advanced solid tumours

    Sponsor / Cooperative group

    Merck

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting